Anzeige
Meldung des Tages: Nach +300 % in 12 Monaten bei Almonty: Startet jetzt die nächste Antimon-Rally?

Johnson & Johnson News

Aktie
WKN:  853260 ISIN:  US4781601046 US-Symbol:  JNJ Branche:  Pharmazeutika Land:  USA
207,10 €
-0,15 €
-0,07%
09:51:24 Uhr
Depot/Watchlist
Marktkapitalisierung *
425,07 Mrd. €
Streubesitz
24,80%
KGV
19,04
Dividende
4,57 EUR
Dividendenrendite
2,61%
Nachhaltigkeits-Score
64 %
Index-Zuordnung
Dow Jones Industrial Average
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,39: UQ8H9G
Werbung

Johnson & Johnson News

18.03.26 - PR Newswire
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-​line systemic treatment of plaque psoriasis with a targeted oral peptide PR Newswire
17.03.26 wallstreetONLINE Redaktion
Marktchaos treibt Anleger um: Dividenden statt KI-Hype: Diese Aktien schlagen 2026 plötzlich den Markt
Marktschwankungen treiben Anleger in defensive Dividendenwerte. Analysten sehen besonders bei sogenannten Dividend Aristocrats jetzt Chancen.Die starken Schwankungen an ...
13.03.26 - PR Newswire
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
Johnson & Johnson highlights promising first-​in-human Erda-iDRS (formerly TAR-210) results in intermediate-​risk non-​muscle-invasive bladder cancer PR Newswire
05.03.26 - PR Newswire
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care ...
05.03.26 n-tv
Goldreserve immer wertvoller: Kein Scheck aus Frankfurt - Bundesbank macht erneut Milliardenminus
Lange Zeit kann der Finanzminister mit einer jährlichen Überweisung der Bundesbank rechnen. Doch diese Zeiten sind vorbei. Zum inzwischen sechsten Mal bleibt die Zahlung ...
05.03.26 - PR Newswire
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
Anxiety Treatment Boom: GAD Therapies Poised for Multi-​Billion Dollar Expansion PR Newswire
03.03.26 - PR Newswire
/C O R R E C T I O N -- Johnson & Johnson/
/C O R R E C T I O N -- Johnson & Johnson/ PR Newswire
26.02.26 - PR Newswire
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer PR Newswire
24.02.26 - PR Newswire
Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-​aahu) as the first-​ever FDA-​approved treatment for warm autoimmune hemolytic anemia (wAIHA) PR Newswire
21.02.26 wallstreetONLINE Redaktion
Community Rückblick: wO-User zur Newron Kapital­erhöhung: "Tja, wir wurden wohl mächtig verarscht"
Newron ist zurück an der Spitze der wallstreetONLINE-​Diskussionen. Grund: Bis zu 38 Mio. € Finanzierung für das Phase-​III-Programm Evenamide (Schizophrenie). Die Community ...
21.02.26 - PR Newswire
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years PR Newswire
19.02.26 - PR Newswire
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-​lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-​line recurrent or ...
18.02.26 - PR Newswire
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-​lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer PR Newswire
17.02.26 - PR Newswire
FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-​lpuj) as the only EGFR-​targeted therapy that can be administered once a month PR Newswire
12.02.26 - ARIVA.DE Redaktion
Mit 1 Million USD in den Ruhestand: Ein Dividenden-Portfolio, das heute schon 4,3 % Rendite abwirft
Ein Portfolio von 1 Million US-Dollar kann nach einem Modell auf Seeking Alpha ein jährliches Dividendeneinkommen von rund 43.000 US-Dollar generieren – bei gleichzeitiger ...
10.02.26 - PR Newswire
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market PR Newswire
27.01.26 - PR Newswire
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible PR Newswire
21.01.26 - ARIVA.DE Redaktion
Die Rekordjagd dieses Dividendenkönigs dürfte erst einmal vorbei sein!
Der US-​Pharmakonzern und Konsumgütergigant Johnson & Johnson hat am Mittwochmittag zufriedenstellende Zahlen vorgelegt. Diese könnten trotzdem zu wenig sein.
21.01.26 wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Frische Quartals­zahlen von Johnson & Johnson, United Airlines und Burberry!
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
14.01.26 - PR Newswire
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
TECVAYLI® monotherapy demonstrates superior progression-​free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma ...

Newssuche

Videos

newspaper
23.03.26 -5,38%
Technical Trading: Gold Long nach Absturz
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »